Anti-Nogo antibody therapy is presently being tested in both acute and chronic SCI through the RESET trial (NCT03989440) and Nogo Inhibition in Spinal Cord Injury (NISCI) clinical trial (NCT03935321), respectively [76]. This evidence concerns the gene RTN4 and spinal cord injury.